Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.

Biologic drugs are big. A heterogeneous mixture of more than 1,300 weighty amino acids, they are hundreds of times the 1- to 2 ml size of conventional small molecule injectables. That renders them hard to make - and even harder for patients to take.

But a new drug delivery system - the large volume wearable injector (LVWI) - has emerged to overcome the unmet needs for formulation and delivery of the more than 900 biologics on the market or in development for treating a broad range of cancers, autoimmune disorders and rare diseases. Partnerships to create patient-focused, differentiated combination products are rapidly proliferating.

The new LVWI devices are optimised to provide dosing flexibility, decrease dependence on healthcare systems, and improve compliance with therapeutic regimens. They give new life to expiring biologics, extending life cycles.

The most advanced LVWI devices available today:

  • Deliver mega-doses of up to 50 ml subcutaneously with a small wearable device
  • Combine the original container closure with a delivery system that is strongly preferred by users,
    saving costs and reducing development time by months
  • Offer patients and caregivers easy, convenient, stress-free at-home (or work) treatment options, replacing IVs
  • Warm and lyophilise in seconds, automatically, while the device fills
  • Adapt injection rate to user, optimising comfort with flow- and pressure-control technology
  • Connect to mobile apps to monitor compliance.